J&J Eyes $3.4 Bn Ollin Biosciences Deal to Expand Eye Disease Drug Pipeline
The reported acquisition would continue J&J's broader strategy of strengthening its pharmaceutical pipeline through targeted acquisitions.
Johnson & Johnson (J&J) has reportedly been in discussions to acquire Texas-based biotechnology company Ollin Biosciences for up to $3.4 Bn, potentially strengthening its presence in treatments for retinal diseases.
Under the terms being discussed, J&J could pay $2.2 Bn in upfront cash, followed by up to $1.2 Bn in additional milestone payments linked to specified development or commercial objectives.
Ollin Biosciences is developing OLN324, an experimental drug intended to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Both conditions affect the retina and can lead to significant vision loss. DME is associated with diabetes-related damage to retinal blood vessels, while wet AMD involves abnormal blood vessel growth beneath the retina.
The company raised $330 Mn in June to support the advancement of OLN324 through late-stage clinical studies. The drug represents a potential opportunity for J&J to expand its portfolio in retinal medicine, although its clinical effectiveness, safety and regulatory prospects will depend on further development and evaluation.
The reported acquisition would also continue J&J's broader strategy of strengthening its pharmaceutical pipeline through targeted acquisitions.
Earlier in 2026, the company acquired biotechnology firm Firefly Bio for $1 Bn in cash to expand its oncology portfolio.
In 2025, J&J completed its $14.6 Bn acquisition of Intra-Cellular Therapies, broadening its presence in treatments for neurological and psychiatric disorders.
For J&J, a deal involving Ollin Biosciences would add an experimental asset focused on two significant causes of vision impairment.
However, the companies have not publicly confirmed the reported negotiations, and the proposed deal could still change.
Stay tuned for more such updates on Digital Health News